Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.56 |
| ▸ | CA1 | P00915 | 5/20 | 0.54 |
| ▸ | CA2 | P00918 | 5/20 | 0.54 |
| ▸ | CA12 | O43570 | 4/20 | 0.54 |
| ▸ | CA9 | Q16790 | 4/20 | 0.54 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.54 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.51 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.50 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.50 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | CA7 | P43166 | 1/20 | 0.48 |
| ▸ | CHKA | P35790 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL765010 | 0.95 | LOXL2 (0.61) | LOXL2CA1CA2CA12CA9 | |
| SCHEMBL14379749 | 0.85 | LOXL2 (0.51) | LOXL2CA1CA2CA12CA9 | |
| SCHEMBL8121457 | 0.85 | PTPN1 (0.55) | LOXL2CYP4A11CXCR1CXCR2CYP4F2 | |
| SCHEMBL9372952 | 0.83 | RAB9A (0.68) | MAPTRAB9A | |
| SCHEMBL13638915 | 0.83 | RAB9A (0.68) | MAPTRAB9A | |
| SCHEMBL12001315 | 0.83 | ACACB (0.59) | — | |
| SCHEMBL25146346 | 0.82 | SLC2A1 (0.49) | LOXL2CYP4A11CXCR1CXCR2CYP4F2 | |
| SCHEMBL5177723 | 0.82 | LOXL2 (0.59) | LOXL2CA1CA2CA12CA9 | |
| SCHEMBL25146756 | 0.82 | CXCR1 (0.57) | CXCR1CXCR2RAB9A | |
| SCHEMBL10243318 | 0.82 | LOXL2 (0.63) | LOXL2CA1CA2CA12CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230117680-A1 | CYCLOPHILIN D INHIBITORS AND USES THEREOF | THE BROAD INSTITUTE, INC. (US) | 2023-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230117680-A1 | CYCLOPHILIN D INHIBITORS AND USES THEREOF | PPID, PPIF, PPIL1 | LOXL2 2566/4885CA1 3294/4885CA2 4397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.